Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
5005 Mcconnell Ave, Los Angeles, CA
State of incorporation
WA
Fiscal year end
December 31
Former names
AmpliPhi Biosciences Corp (to 5/8/2019), TARGETED GENETICS CORP /WA/ (to 2/11/2011)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 31 % -64%
Debt-to-equity -329 % -161%
Return On Equity 89.1 %
Return On Assets -38.9 % +31.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares +0.1%
Common Stock, Shares, Outstanding 36.2M shares +0.17%
Entity Public Float 12.5M USD -70.2%
Common Stock, Value, Issued 362K USD +0.28%
Weighted Average Number of Shares Outstanding, Basic 36.2M shares +0.26%
Weighted Average Number of Shares Outstanding, Diluted 36.2M shares +0.26%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13M USD +26.8%
Operating Income (Loss) -41.5M USD +0.39%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -41.4M USD +30.5%
Earnings Per Share, Basic -1.14 USD/shares +30.5%
Earnings Per Share, Diluted -1.57 USD/shares +8.19%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.1M USD -28.5%
Other Assets, Current 2.22M USD -73.9%
Assets, Current 22.4M USD -38.8%
Property, Plant and Equipment, Net 13.6M USD +47.2%
Operating Lease, Right-of-Use Asset 42.3M USD -5.87%
Intangible Assets, Net (Excluding Goodwill) 10.3M USD 0%
Goodwill 3.49M USD 0%
Other Assets, Noncurrent 755K USD -69.4%
Assets 98.2M USD -12.9%
Accounts Payable, Current 1.82M USD -51.9%
Liabilities, Current 118M USD +440%
Deferred Income Tax Liabilities, Net 3.08M USD 0%
Operating Lease, Liability, Noncurrent 27.9M USD -0.83%
Liabilities 149M USD +19.2%
Retained Earnings (Accumulated Deficit) -330M USD -14.3%
Stockholders' Equity Attributable to Parent -51M USD -312%
Liabilities and Equity 98.2M USD -12.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +39.8%
Net Cash Provided by (Used in) Financing Activities 34.9M USD +18%
Net Cash Provided by (Used in) Investing Activities -250K USD +87.6%
Common Stock, Shares Authorized 217M shares 0%
Common Stock, Shares, Issued 36.2M shares +0.17%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 24.1M USD +141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.6M USD -24%
Operating Lease, Liability 32.9M USD
Depreciation 1.3M USD +48.7%
Payments to Acquire Property, Plant, and Equipment 250K USD -87.6%
Lessee, Operating Lease, Liability, to be Paid 66.1M USD
Property, Plant and Equipment, Gross 26.4M USD +25.5%
Operating Lease, Liability, Current 4.99M USD -62.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.29M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 5.14M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33.2M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.45M USD
Deferred Tax Assets, Operating Loss Carryforwards 42.5M USD +16.8%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.62M USD
Operating Lease, Payments 3.36M USD -35.4%
Additional Paid in Capital 279M USD +1.01%
Depreciation, Depletion and Amortization 317K USD +37.8%
Share-based Payment Arrangement, Expense 2.73M USD +74.9%
Interest Expense 2.72M USD